Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression

NCT00747240 | Completed

• 1 other identifier: 00008854
• Study Type: observational
• Target: 139
• Locations: 1 country
• Sites: 2

Brief Summary

This is a prospective observational study to determine whether there is an association between the presence of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms and the development of chronic lung disease in very low birth wight infants. Infants \< 1500 grams at birth who require mechanical ventilation will be enrolled in the first 5 days of life after obtaining informed consent. A total of 1 ml of blood will be drawn and utilized for isolation of DNA for genotyping and for measurement of PAF-AH activity in serum.

Conditions

Low Birth Weight Infant

Keywords

Ile198Thr; Ala379Val; variants; PAF-AH

Outcome Measures

Primary Outcomes (1)

• Incidence of Chronic Lung Disease (CLD) and survival at 36 weeks corrected gestational age (CGA).

  CLD will be defined as an oxygen requirement and abnormal x-ray findings. Investigations will compare outcomes of participants with genotypic variants of PAF-AH and those without known PAF-AH polymorphisms. Also, participant with biochemical evidence of PAF-AH dysregulation will be compared to those with normal PAF-AH protein and PAF concentrations.

  at 36 weeks (CGA)

Secondary Outcomes (1)

• PAF-AH genotypic and phenotypic status in relation to multiple morbidities associated with prematurity.

  18 months

Eligibility Criteria

• Age: Up to 5 Days
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Eligible Patients Patients hospitalized in the NICU who: 1. weigh ≤ 1500 grams at birth, 2. are enrolled at age ≤ 5 days, 3. require mechanical ventilation or continuous positive airway pressure (CPAP), 4. have parents or guardians that have signed the informed consent document. Excluded Patients Infants with major congenital anomalies will be excluded.

You may qualify if:

• Patients hospitalized in the NICU who:
• weigh ≤ 1500 grams at birth,
• are enrolled at age ≤ 5 days,
• require mechanical ventilation or continuous positive airway pressure (CPAP),
• have parents or guardians that have signed the informed consent document.

You may not qualify if:

• Infants with major congenital anomalies will be excluded.

Sponsors & Collaborators

• University of Utah: lead

Study Sites (2)

University of Utah

Salt Lake City, Utah, 84108, United States

Location

Primary Children's Medical Center

Salt Lake City, Utah, 84112, United States

Location

Study Officials

• Christian C Yost, M.D.

  University of Utah

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 3, 2008
• First Posted: September 5, 2008
• Study Start: February 1, 2002
• Primary Completion: December 1, 2014
• Study Completion: December 1, 2014
• Last Updated: May 12, 2015

Record last verified: 2014-07

Locations

US (2)